These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31649375)

  • 1. Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
    Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Saito AM; Iwasaki H
    Acta Med Okayama; 2019 Oct; 73(5):469-474. PubMed ID: 31649375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.
    Yamasaki S; Iida H; Saito A; Matsumoto M; Kuroda Y; Izumi T; Saito AM; Miyoshi H; Ohshima K; Nagai H; Iwasaki H
    Hematol Rep; 2024 May; 16(2):336-346. PubMed ID: 38921182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
    Reiman T; Savage KJ; Crump M; Cheung MC; MacDonald D; Buckstein R; Couban S; Piliotis E; Imrie K; Spaner D; Shivakumar S; Kuruvilla J; Villa D; Shepherd LE; Skamene T; Winch C; Chen BE; Hay AE
    Leuk Lymphoma; 2019 Apr; 60(4):912-919. PubMed ID: 30301414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.
    Yao YY; Tang Y; Zhu Q; Zhuang Y; Cheng YM; Wang L; Zou LF
    Leuk Lymphoma; 2013 Jun; 54(6):1194-200. PubMed ID: 23061678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
    Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
    Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
    Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
    Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
    Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
    Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study
    Skamene T; Crump M; Savage KJ; Reiman T; Kuruvilla J; Good D; LeBrun D; Meyer RM; Sehn LH; Soulières D; Stakiw J; Laferriere N; Luminari S; Shepherd LE; Djurfeldt M; Zhu L; Chen BE; Hay AE
    Leuk Lymphoma; 2017 Oct; 58(10):2319-2327. PubMed ID: 28504033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
    Aota Y; Tanaka M; Watanabe N; Tomomatu J; Gotoh A; Komatu N
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):51-5. PubMed ID: 25596679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma.
    Kato H; Yamamoto K; Higuchi Y; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Chemotherapy; 2017; 62(1):19-22. PubMed ID: 27226129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol.
    Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Miyata Y; Miyazawa Y; Saito A; Iwasaki H
    Kurume Med J; 2020 Jul; 66(1):37-42. PubMed ID: 31787704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
    Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
    J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.